Intellicell Biosciences Inc (fka SVFC)

[chosenuno]

NEWS!!

NEW YORK, NY -- (Marketwired) -- 03/17/14 -- IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed consulting agreements with Dr Adam Anz and Dr Josh Hackel of the Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida . Intellicell will be filing an IND for the treatment of osteoarthritis of knee lead by Dr. James Andrews and conducted by Drs. Anz and Hackel for its Stromal Vascular Fraction Cells (SVFC).
IntelliCell's Chief Executive Officer, Dr. Steven Victor , remarked, "I am excited that the company will be filing its first IND for osteoarthritis of the knee and has the honor to be working with Dr. Andrews, Dr. Anz and Dr. Hackel. They are the some of the most prominent sports medicine physicians in the company. Dr. Anz and Dr. Hackel bring their vast knowledge and experience in stem cells to this project. With this distinguished group of doctors on board we will be able to advance the research and science of the SVF cellular product in the fields of orthopedic and sports medicine."
As said by Dr. Adam Anz , "Dr. Victor, through Intellicell Biosciences , has been a pioneer in the clinical application of stem cell therapy in the United States . His interactions with the FDA have helped us understand the current regulatory status, and he has a practice, which recently has passed their scrutiny. At the Andrews Research and Education Institute , we look forward to collaborating with him and to applying his technology in a compliant fashion. Working together we will produce evidence about the value of stem cell therapy for the treatment of joint injuries and degeneration, which will help us treat our patients better."
According to Dr. Josh Hackel , "We have recognized IntelliCell BioSciences as a forward thinking company and we are excited to continue FDA compliant research in this area as it relates to sports medicine and the treatment of our patients. It will be research like this at the Andrews Research and Education Institute in collaboration with IntelliCell BioSciences that will further our understanding and improve our management of sports medicine injuries."